Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

HBW Over The Counter Podcast
• Source: Citeline Design Team

Interest in the human gut microbiome and the influence it exerts on a person’s wellbeing, from cognitive health to immunity, has been rapidly increasing in recent years.

In this episode of HBW Insight's Over the Counter podcast, we speak to Dublin-based food company Kerry Group about a particularly exciting, emerging area of microbiome-based wellness, postbiotics, which are defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.”

Given that postbiotics rely on inanimate ingredients, rather than live cultures as in yoghurts, they may provide more suitable vehicles for consumer health innovation, suggests Kerry Group’s RDA senior manager of immune and joint health, Sonja Nodland.

Nodland also explains what kinds of postbiotics are currently on the European market, for example for digestive and skin health and immunity, and the regulatory challenges that postbiotics share with other microbiome products in the region, such as pre- and pro-biotics.

Open Media

Timestamps

2:20 Introductions

4:00 What are postbiotics?

8:30 Advantages of postbiotics for consumer health innovation

10:20 Health benefits of postbiotics

12:00 Types of postbiotics

15:20 Kerry’s postbiotic portfolio

19:00 Postbiotic regulation in the European Union

28:00 Where to start with postbiotic innovation

Guest Bio

Sonja Nodland, PhD is Senior RDA Manager for Immune and Joint Health at Kerry. She conducted her graduate studies at Washington University in St. Louis and the University of Minnesota studying both molecular mechanisms of microbial pathogenesis and cancer and human immunology. After finishing her postdoctoral research at the University of Minnesota in basic human developmental immunology she joined a pharmaceutical startup company to combine her scientific interests in immunology and the health effects of microbial products on the human immune system. Her current scientific interests are related to the relationship of microbiome health to human immune health and the pleiotropic effects of microbial-derived products on human general health.

More from Europe

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

 
• By 

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

‘Nothing Unexpected’ In Third Failed Application For OTC Sildenafil In Germany

 
• By 

“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By 

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.

New Product Launches Ensured Growth For Stada CHC In 2024

 
• By 

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.

More from Geography

New Product Launches Ensured Growth For Stada CHC In 2024

 
• By 

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.

Maxwellia Launches UK TV Campaign For Evana Showing Reality Of Menstruation

 
• By 

Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”

Over The Counter: Women’s Health Innovation And Beyond, With Maxwellia’s Anna Maxwell

 
• By 

HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.